pMSCV-FlagMLL-pl-ENL(5613) Citations (5)

Originally described in: Alterations of the CxxC domain preclude oncogenic activation of mixed-lineage leukemia 2.
Bach C, Mueller D, Buhl S, Garcia-Cuellar MP, Slany RK Oncogene. 2009 Feb 12. 28(6):815-23. PubMed Journal

---

Articles Citing pMSCV-FlagMLL-pl-ENL(5613)

Articles
KMT2A promotes melanoma cell growth by targeting hTERT signaling pathway. Zhang C, Song C, Liu T, Tang R, Chen M, Gao F, Xiao B, Qin G, Shi F, Li W, Li Y, Fu X, Shi D, Xiao X, Kang L, Huang W, Wu X, Tang B, Deng W. Cell Death Dis. 2017 Jul 20;8(7):e2940. doi: 10.1038/cddis.2017.285. PubMed
ASH2L is involved in promotion of endometrial cancer progression via upregulation of PAX2 transcription. Zeng K, Wu Y, Wang C, Wang S, Sun H, Zou R, Sun G, Song H, Liu W, Sun N, Wei S, Liu W, Su Y, Zhou T, Zhang Y, Zhao Y. Cancer Sci. 2020 Jun;111(6):2062-2077. doi: 10.1111/cas.14413. Epub 2020 May 23. PubMed
GATA3 (GATA-Binding Protein 3)/KMT2A (Lysine-Methyltransferase-2A) Complex by Increasing H3K4-3me (Trimethylated Lysine-4 of Histone-3) Upregulates NCX3 (Na(+)-Ca(2+) Exchanger 3) Transcription and Contributes to Ischemic Preconditioning Neuroprotection. Guida N, Mascolo L, Serani A, Cuomo O, Anzilotti S, Brancaccio P, Pignataro G, Molinaro P, Annunziato L, Formisano L. Stroke. 2021 Nov;52(11):3680-3691. doi: 10.1161/STROKEAHA.121.034637. Epub 2021 Oct 25. PubMed
Multi-omics reveals mitochondrial metabolism proteins susceptible for drug discovery in AML. Caplan M, Wittorf KJ, Weber KK, Swenson SA, Gilbreath TJ, Willow Hynes-Smith R, Amador C, Hyde RK, Buckley SM. Leukemia. 2022 May;36(5):1296-1305. doi: 10.1038/s41375-022-01518-z. Epub 2022 Feb 17. PubMed
Myeloid Targeted Human MLL-ENL and MLL-AF9 Induces cdk9 and bcl2 Expression in Zebrafish Embryos. Belt AJ, Grant S, Tombes RM, Rothschild SC. PLoS Genet. 2024 Jun 3;20(6):e1011308. doi: 10.1371/journal.pgen.1011308. eCollection 2024 Jun. PubMed

If you have published an article using this material, please email us at to have your article added to this page.